BIBW 2992 (Afatinib) in Head & Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 124
- Registration Number
- NCT00514943
- Locations
- 🇺🇸
1200.28.0024 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸1200.28.0001 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸1200.28.0010 Boehringer Ingelheim Investigational Site, Stanford, California, United States
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 432
- Registration Number
- NCT00514683
- Locations
- 🇦🇷
1199.30.54002 Boehringer Ingelheim Investigational Site, Mendoza, Argentina
🇧🇪1199.30.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
🇧🇪1199.30.32002 Boehringer Ingelheim Investigational Site, Yvoir, Belgium
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients
- Conditions
- Interventions
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 539
- Registration Number
- NCT00479401
- Locations
- 🇭🇺
248.524.36008 Boehringer Ingelheim Investigational Site, Miskolc, Hungary
🇮🇳248.524.91010 Boehringer Ingelheim Investigational Site, Hyderabad, India
🇮🇳248.524.91001 Boehringer Ingelheim Investigational Site, Karnataka, India
Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 331
- Registration Number
- NCT00472199
- Locations
- 🇬🇧
248.629.44003 Boehringer Ingelheim Investigational Site, Chorley, United Kingdom
🇪🇸248.629.3402 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇬🇧248.629.44004 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
- Conditions
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 296
- Registration Number
- NCT00467740
- Locations
- 🇨🇦
1222.6.004 Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada
🇨🇦1222.6.006 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇺🇸1222.6.073 Boehringer Ingelheim Investigational Site, Wheat Ridge, Colorado, United States
Pivotal Study in Advanced Parkinsons Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 517
- Registration Number
- NCT00466167
- Locations
- 🇦🇹
248.525.43005 Boehringer Ingelheim Investigational Site, Linz, Austria
🇰🇷248.525.82008 Boehringer Ingelheim Investigational Site, Kyeonggi-do, Korea, Republic of
🇮🇹248.525.39005 Università La Sapienza di Roma, Roma, Italy
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
- Conditions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 409
- Registration Number
- NCT00452400
- Locations
- 🇺🇸
1222.5.02 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇨🇦1222.5.040 Respiratory Research Lab, Toronto, Ontario, Canada
🇨🇦1222.5.034 Pulmonary Care Clinic and Research Centre, Toronto, Ontario, Canada
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
- Conditions
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11
- Registration Number
- NCT00447902
- Locations
- 🇺🇸
1182.99.31 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇫🇷1182.99.3306K Boehringer Ingelheim Investigational Site, Nantes, France
🇩🇪1182.99.4909 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC
- Conditions
- Interventions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33
- Registration Number
- NCT00440271
- Locations
- 🇺🇸
1182.98.018 Boehringer Ingelheim Investigational Site, Clearwater, Florida, United States
🇺🇸1182.98.014 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇺🇸1182.98.004 Boehringer Ingelheim Investigational Site, Decatur, Georgia, United States
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT00431067
- Locations
- 🇺🇸
1200.11.4 Boehringer Ingelheim Investigational Site, Santa Monica, California, United States
🇺🇸1200.11.7 Boehringer Ingelheim Investigational Site, Encinitas, California, United States
🇺🇸1200.11.3 Boehringer Ingelheim Investigational Site, Scottsdale, Arizona, United States